AbCellera Biologics Inc. announced the European Commission and Eli Lilly and Company have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. The agreement helps to provide access to treatments by enabling participating countries in the European Union and European Economic Area to purchase the products directly from Lilly following national approval for emergency use or marketing authorization at the EU level.